GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
1.5k
c/retatrutide·posted 1 months ago by u/nadia_norgaard

small win: glucagon stopped being a problem at week 32

Trial Data The Quiet One ×9 Slow Clap ×2

Six-word version is the title — small win: glucagon stopped being a problem at week 32 — and the rest is context.

Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.

The fatigue profile felt different rather than worse. Hard to describe and impossible to quantify, so take it as an impression.

I will update this if the picture changes rather than quietly leaving it up.

12,516 up / 11,004 down53% upvoted45 commentsid v2bvyq6 Jun 2026

45 comments

12 in this archive, depth 4

best — the order this archive was captured in

u/endotoxin_elliemicro328 points·1 months ago·edited

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

replysharereportpermalink
u/andres_sorensen126 points·1 months ago

Stopped at a low step because there was no reason to go further and no data to tell me what further would do.

replysharereportpermalink
u/incretin_ivypharmacology57 points·1 months ago

comparing reta phase 2 to sema phase 3 is comparing different things

replysharereportpermalink
u/kavya_kravchenko230 points·1 months ago

Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.

replysharereportpermalink
u/nadia_trevino0 points·1 months ago

a lot of the confident posting here is extrapolation

replysharereportpermalink
u/kofi_balogun1 point·1 months ago

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

replysharereportpermalink
u/titration_marshalmod · c/semaglutide1 point·1 months ago

Sceptical of the extrapolation. Forty-eight weeks does not tell you about seventy-two, and the curve shape is exactly what is unknown.

replysharereportpermalink
u/soren_nkemelu1 point·1 months ago

That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.

replysharereportpermalink
u/crosspost_bot_no0 points·1 months ago

a lot of the confident posting here is extrapolation

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

replysharereportpermalink
u/incretin_ivypharmacology0 points·1 months ago

Not convinced. You are attributing a week of sulphur burps to the glucagon arm when the escalation rate alone would explain it.

replysharereportpermalink
u/rohan_cardoso0 points·1 months ago

Not convinced.

Adding the standing caveat: none of this is approved anywhere and research material is not for human use.

replysharereportpermalink
u/andres_restrepo1 point·1 months ago

Agreed on the heart-rate reports. They are consistent enough across the threads to be worth noting, not enough to be a finding.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/retatrutide

Retatrutide: GIP/GLP-1/glucagon triple agonism, the TRIUMPH programme, and the fact that most people discussing it are handling research-grade material with no human-use approval anywhere. Dose-response, heart-rate signal, and the unusually steep phase-2 weight curves get argued about here weekly.

65kmembers
130submissions
Sep 2023created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/retatrutide rules
  1. Retatrutide is not approved anywhere for human use. Posts must not read as usage instructions.
  2. Phase 2 numbers are not maintenance numbers. Cite the trial and the dose arm.
  3. Heart-rate and dose-escalation reports need actual measurements, not impressions.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.